| REVIEW ARTICLE |
|
| Year : 2018 | Volume
: 34
| Issue : 3 | Page : 172-179 |
|
|
Positron emission tomography in prostate cancer: An update on state of the art
Chandan Jyoti Das, Abdul Razik, Sanjay Sharma
Department of Radio-Diagnosis, All India Institute of Medical Sciences, New Delhi, India
Correspondence Address:
Chandan Jyoti Das
Department of Radio-Diagnosis, All India Institute of Medical Sciences, New Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/iju.IJU_320_17
|
|
|
Prostate cancer (PCa), one of the most common cancers in males, is a topic of active interest in imaging research. Positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance imaging (PET/MRI) have enabled the combination of morphologic and functional imaging with the promise of providing better information in guiding therapy. 18F-fluorodeoxyglucose, the workhorse radiopharmaceutical in PET imaging, has not found preference in PCa since these tumors show poor glucose uptake and can be obscured by the normal urinary excretion of the radiotracer. Hence, the last two decades have seen the development of multiple newer radiotracers and better optimization of the technical aspects of PET imaging. The combination of functional imaging and MRI holds great promise. We searched PubMed, Scopus, and Google Scholar for peer-reviewed literature concerning the advances and newer developments in the imaging of PCa between the years 2005 and 2017. This review aims at summarizing current evidence on the role of PET imaging in PCa and its impact on the diagnosis, staging, prognostication, response assessment, and restaging of this malignancy. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
